Research Candidates

 
News Articles for Research Candidates top ^
2014/11/6
MILWAUKEE , Nov.
Sign-up for Right CareerExpo Offers Employers Virtual, No-Cost Access to Skilled Candidates investment picks
--Candidate Will Target Two Undisclosed Immune Checkpoints --Anti-TIM-3 Antibody Data to be Presented Today at the AACR Conference in Orlando WALTHAM, Mass.
Sign-up for TESARO and AnaptysBio Expand Immuno-Oncology Collaboration to Include Novel Bispecific Antibody Candidate investment picks
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “entrectinib” for the company’s lead product candidate, RXDX-101.
Sign-up for Ignyta Receives Approval of Nonproprietary Name Entrectinib for Lead Product Candidate, RXDX-101 investment picks
2014/12/22
Only 7 percent of hiring managers report that “nearly all” or “most” job seekers have the right combination of skills and traits to fill open positions.
Sign-up for Hiring Managers Struggle to Find Candidates Who “Fit” investment picks
- IND application for Phase 1 clinical trial of IMO-9200 in healthy volunteers accepted by FDA; patient dosing on track to begin in fourth quarter CAMBRIDGE, Mass., Oct.
Sign-up for Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 investment picks
Novavax's stock (NVAX) surged 12% in premarket trade Monday after the drug maker said it expects to initiate a Phase 1 clinical trial of its Ebola vaccine in December.
Sign-up for Novavax's stock surges after news of Ebola vaccine candidate trial investment picks
2014/10/27
--Top-line Results Confirming Safety, Liver Transfection Presented at ESGCT Conference--
Sign-up for AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data from Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate investment picks
Sustained Immune Responses Protecting the Lung and Nose Against RSV Challenge Seen GAITHERSBURG, Md.
Sign-up for Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium investment picks
In Voting Overwhelmingly on Broadfin's Gold Proxy Card Shareholders Followed the Recommendations of ISS and Glass Lewis Broadfin Looks Forward to a Refreshed Board with Five Recent Additions and the Opportunity to Create Immediate Positive Impact NEW YORK , Dec.
Sign-up for Broadfin Capital Thanks Shareholders For Their Overwhelming Support In Electing Its Three Director Candidates To The Board Of Directors Of Cardica investment picks
The estimated global market of Rheumatoid Arthritis is expected to reach $38B in 2017 PETACH TIKVA, Israel , Dec.
Sign-up for Can-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101 investment picks
AMES, Iowa and KENILWORTH, N.J., Dec.
Sign-up for NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award investment picks
DURHAM, N.C. and EDISON, N.J., Dec.
Sign-up for Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157 investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Candidates
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Campus  |  Next: Research Capabilities